Belimumab 10 mg/kg

DRUG9 trials

Conditions

Arthritis, RheumatoidLupus Erythematosus, DiscoidLupus Erythematosus, SystemicSystemic Lupus ErythematosusVasculitis

Phase 2

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

CompletedNCT00071487

Human Genome Sciences Inc.Lupus Erythematosus, Systemic

Start: 2003-10-31End: 2006-06-30Updated: 2013-08-07

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

CompletedNCT00071812

Human Genome Sciences Inc.Arthritis, Rheumatoid

Start: 2003-12-31End: 2005-12-31Updated: 2013-08-14

Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy

CompletedNCT01649765

GlaxoSmithKlineSystemic Lupus Erythematosus

Start: 2012-09-07End: 2025-09-30Updated: 2026-04-20

Phase 3

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

CompletedNCT00410384

Human Genome Sciences Inc.Systemic Lupus Erythematosus

Start: 2006-12-31End: 2010-03-31Updated: 2017-02-01

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

CompletedNCT00424476

Human Genome Sciences Inc.Systemic Lupus Erythematosus

Start: 2007-05-31End: 2010-03-31Updated: 2016-12-12

A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

CompletedNCT00724867

Human Genome Sciences Inc., a GSK CompanySystemic Lupus Erythematosus

Start: 2008-08-31End: 2015-03-31Updated: 2016-03-28

Belimumab in Remission of VASculitis

CompletedNCT01663623

Human Genome Sciences Inc., a GSK CompanyVasculitis

Start: 2013-03-20End: 2017-02-06Updated: 2018-04-17

Unknown Phase

A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies

CompletedNCT01858792

Human Genome Sciences Inc., a GSK CompanyLupus Erythematosus, Discoid

Start: 2011-05-31End: 2011-06-30Updated: 2013-05-21

Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76

CompletedNCT01914770

GlaxoSmithKlineSystemic Lupus Erythematosus

Start: 2009-07-31End: 2010-11-30Updated: 2013-09-16

2026-07-03

Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.

2026-05-21

PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a <i>post-hoc</i> summary of five phase 3 trials

Reumatismo2025-11-26

Application of Bayesian statistics to support approval of intravenous belimumab in children with systemic lupus erythematosus in the United States

Lupus2025-06-274 citations

The effect of belimumab on mucocutaneous and vasculitis manifestations in patients with systemic lupus erythematosus: A large pooled post hoc analysis

Lupus2025-05-052 citations

Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.

2025-02-015 citations

Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms

Rheumatology Advances in Practice2025-01-011 citations

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

2024-09-017 citations

Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.

2024-08-2615 citations

SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus

Lupus Science & Medicine2024-05-012 citations

Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better <scp>Health‐Related</scp> Quality of Life

Arthritis Care & Research2024-01-233 citations

Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review

Current Therapeutic Research2024-01-013 citations

LSO-068 Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-fatigue scores in patients with SLE

2023-07-01

LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab

2023-07-01

LSO-030 Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab

2023-07-01

Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials

Lara D. Veeken2023-05-2537 citations

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State

Lara D. Veeken2023-03-215 citations

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus

Frontiers in Medicine2022-12-2012 citations

PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus

2022-09-27

PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE

2022-09-27

31 more papers not shown

Belimumab 10 mg/kg

Sponsors

Conditions

Phase 2

Phase 3

Unknown Phase

Related Papers